Compare LOAN & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | RNXT |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 42.4M |
| IPO Year | 1999 | 2021 |
| Metric | LOAN | RNXT |
|---|---|---|
| Price | $4.00 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 22.4K | ★ 526.4K |
| Earning Date | 04-16-2026 | 05-14-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $8,666,307.00 | $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | $19.38 | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $3.90 | $0.70 |
| 52 Week High | $5.79 | $1.56 |
| Indicator | LOAN | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 68.67 |
| Support Level | $4.03 | $0.83 |
| Resistance Level | $4.26 | $1.51 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 35.96 | 86.96 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.